Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 4935
1. Xinqiang S, Mu Z, Lei C, Mun LY: Bioinformatics Analysis on Molecular Mechanism of Green Tea Compound Epigallocatechin-3-Gallate Against Ovarian Cancer. Clin Transl Sci; 2017 Jul;10(4):302-307
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bioinformatics Analysis on Molecular Mechanism of Green Tea Compound Epigallocatechin-3-Gallate Against Ovarian Cancer.
  • Epigallocatechin-3-gallate (EGCG) is the most abundant and biologically active catechin in green tea, and it exerts multiple effects in humans through mechanisms that remain to be clarified.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
  • [Cites] Exp Biol Med (Maywood). 2006 Jun;231(6):1123-7 [16741061.001]
  • [Cites] Nutrients. 2016 Sep 09;8(9): [27618095.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):101-2 [15639276.001]
  • [Cites] Lancet. 1997 Jan 11;349(9045):113-7 [8996432.001]
  • [Cites] Arch Intern Med. 2005 Dec 12-26;165(22):2683-6 [16344429.001]
  • [Cites] Carcinogenesis. 1998 Apr;19(4):611-6 [9600345.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):713-8 [12163323.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2500-5 [16510563.001]
  • [Cites] Anticancer Res. 2011 Apr;31(4):1131-40 [21508356.001]
  • [Cites] Front Biosci (Elite Ed). 2012 Jan 01;4:111-31 [22201858.001]
  • [Cites] Cancer Epidemiol. 2013 Feb;37(1):54-9 [23107758.001]
  • [Cites] Am J Clin Nutr. 2012 May;95(5):1172-81 [22440851.001]
  • [Cites] Mol Cancer Ther. 2006 Jun;5(6):1483-92 [16818507.001]
  • [Cites] Nutr Cancer. 2011;63(6):817-26 [21800977.001]
  • [Cites] J Agric Food Chem. 2003 Jul 16;51(15):4427-35 [12848521.001]
  • [Cites] Arch Pharm Res. 2000 Dec;23(6):605-12 [11156183.001]
  • [Cites] Evid Based Complement Alternat Med. 2009 Dec;6(4):523-30 [18955299.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Mar;17 (3):712-6 [18349292.001]
  • [Cites] Oncol Rep. 2010 Mar;23(3):605-14 [20126997.001]
  • [Cites] Gynecol Oncol. 2012 Sep;126(3):491-8 [22564714.001]
  • [Cites] Nutrients. 2012 Nov 08;4(11):1679-91 [23201840.001]
  • [Cites] Genes Nutr. 2011 May;6(2):109-15 [21484164.001]
  • [Cites] J Agric Food Chem. 2000 Jul;48(7):2848-52 [10898634.001]
  • [Cites] Mol Cell Biochem. 2005 May;273(1-2):109-16 [16013445.001]
  • [Cites] Mutat Res. 2004 Nov 2;555(1-2):3-19 [15476848.001]
  • [Cites] Biomed Sci Instrum. 2015;51:31-9 [25996696.001]
  • [Cites] Cancer Res Treat. 2004 Oct;36(5):315-23 [20368822.001]
  • [Cites] Enzymes. 2014;36:195-221 [27102705.001]
  • [Cites] Crit Rev Food Sci Nutr. 2005;45(4):287-306 [16047496.001]
  • [Cites] J Obstet Gynaecol Res. 2006 Apr;32(2):148-54 [16594917.001]
  • [Cites] Anticancer Res. 2010 Jul;30(7):2519-23 [20682977.001]
  • (PMID = 28504421.001).
  • [ISSN] 1752-8062
  • [Journal-full-title] Clinical and translational science
  • [ISO-abbreviation] Clin Transl Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Rafieian-Kopaei M, Movahedi M: Breast cancer chemopreventive and chemotherapeutic effects of Camellia Sinensis (green tea): an updated review. Electron Physician; 2017 Feb;9(2):3838-3844
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer chemopreventive and chemotherapeutic effects of Camellia Sinensis (green tea): an updated review.
  • This review article is aimed to overview breast cancer chemopreventive and chemotherapeutic effects of Camellia sinensis (green tea).
  • CONCLUSION: Camellia sinensis is broadly utilized as a part of customary medication since antiquated time because of its cost adequacy, and fewer reaction properties.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Hematol Disord Drug Targets. 2007 Jun;7(2):135-44 [17584048.001]
  • [Cites] Pharmacology. 2014;94(5-6):245-8 [25471334.001]
  • [Cites] Front Microbiol. 2014 Aug 20;5:434 [25191312.001]
  • [Cites] Am J Clin Nutr. 2013 Dec;98(6 Suppl):1676S-1681S [24172305.001]
  • [Cites] J Hum Nutr Diet. 2015 Jun;28(3):272-82 [24646362.001]
  • [Cites] Vasc Cell. 2013 May 02;5(1):9 [23638734.001]
  • [Cites] J Nutr. 2002 Aug;132(8):2307-11 [12163680.001]
  • [Cites] J Immunol Res. 2016;2016:4962351 [27191001.001]
  • [Cites] Springerplus. 2013 May 24;2(1):240 [23750333.001]
  • [Cites] World J Clin Oncol. 2014 Aug 10;5(3):520-8 [25114865.001]
  • [Cites] RSC Adv. 2014 Aug 5;4(66):35242-35250 [25243063.001]
  • [Cites] J Evid Based Complementary Altern Med. 2015 Dec 17;:null [26682768.001]
  • [Cites] Mol Cancer. 2010 Oct 14;9:274 [20946668.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4524-9 [10200295.001]
  • [Cites] World J Gastroenterol. 2013 Jun 28;19(24):3713-22 [23840110.001]
  • [Cites] J Hum Nutr Diet. 2010 Dec;23(6):590-600 [20807303.001]
  • [Cites] Arch Intern Med. 2003 Jun 23;163(12):1448-53 [12824094.001]
  • [Cites] Antiviral Res. 2003 Apr;58(2):167-73 [12742577.001]
  • [Cites] Eur J Cancer Prev. 2014 Mar;23(2):84-9 [23939462.001]
  • [Cites] Int J Surg. 2013;11(9):811-5 [23994005.001]
  • [Cites] Nutr Cancer. 2014;66(1):57-67 [24274352.001]
  • [Cites] Pharmacol Res. 2011 Aug;64(2):146-54 [21193040.001]
  • [Cites] Breast Cancer Res. 2015 Jan 31;17:15 [25637171.001]
  • [Cites] Oncol Rep. 2010 Aug;24(2):563-9 [20596647.001]
  • [Cites] J Nutr Biochem. 2014 Apr;25(4):395-403 [24561153.001]
  • [Cites] Eur J Pharmacol. 2009 Mar 15;606(1-3):172-9 [19171136.001]
  • [Cites] Cancer Epidemiol. 2016 Feb;40:73-8 [26680603.001]
  • [Cites] Nutr Res. 2013 Mar;33(3):180-7 [23507223.001]
  • [Cites] J Res Med Sci. 2014 Dec;19(12):1203-4 [25709665.001]
  • [Cites] Int J Surg. 2013;11(4):332-7 [23459184.001]
  • [Cites] Front Biosci (Elite Ed). 2012 Jan 01;4:111-31 [22201858.001]
  • [Cites] J Renal Inj Prev. 2013 Nov 09;3(2):47-9 [25340167.001]
  • [Cites] Phytomedicine. 2010 Jan;17(1):3-13 [19959000.001]
  • [Cites] Int J Cancer. 2009 Mar 15;124(6):1404-8 [19048616.001]
  • [Cites] Crit Rev Food Sci Nutr. 1997 Dec;37(8):693-704 [9447270.001]
  • [Cites] Carcinogenesis. 2008 Oct;29(10):1967-72 [18669903.001]
  • [Cites] Front Oncol. 2013 Dec 13;3:298 [24380073.001]
  • [Cites] Iran J Public Health. 2014 Sep;43(9):1311-3 [26175992.001]
  • [Cites] J Evid Based Complementary Altern Med. 2016 Sep 11;:null [27620926.001]
  • [Cites] Curr Pharm Des. 2016;22(3):277-85 [26561063.001]
  • [Cites] Arch Biochem Biophys. 2010 Sep 1;501(1):65-72 [20558130.001]
  • [Cites] Breast Cancer Res Treat. 2015 Feb;149(3):655-68 [25663548.001]
  • [Cites] Breast Cancer Res. 2010;12 (5):R88 [22889409.001]
  • [Cites] Oxid Med Cell Longev. 2012;2012:984219 [22666523.001]
  • [Cites] Am J Clin Nutr. 2000 Jun;71(6 Suppl):1698S-702S; discussion 1703S-4S [10837321.001]
  • [Cites] Curr Pharm Des. 2016;22(2):238-46 [26561062.001]
  • [Cites] Ann N Y Acad Sci. 2001 Apr;928:274-80 [11795518.001]
  • [Cites] PLoS One. 2014 Jan 30;9(1):e87580 [24498143.001]
  • [Cites] Iran J Kidney Dis. 2015 Nov;9(6):421-6 [26552347.001]
  • [Cites] J Evid Based Complementary Altern Med. 2016 Jul;21(3):221-7 [26232244.001]
  • [Cites] J Renal Inj Prev. 2016 Aug 09;5(3):123-8 [27689107.001]
  • [Cites] Cancer Genomics Proteomics. 2010 Sep-Oct;7(5):261-77 [20952761.001]
  • [Cites] Integr Cancer Ther. 2005 Jun;4(2):144-55 [15911927.001]
  • [Cites] Bioorg Med Chem. 2010 Feb;18(3):1252-8 [20045338.001]
  • [Cites] Mol Nutr Food Res. 2011 Jun;55(6):844-54 [21538850.001]
  • [Cites] Food Chem Toxicol. 2015 Sep;83:26-35 [26051348.001]
  • [Cites] Cancer Causes Control. 2015 Oct;26(10 ):1405-19 [26206423.001]
  • [Cites] J Nutr. 2009 Feb;139(2):310-6 [19074205.001]
  • [Cites] PLoS One. 2014 May 14;9(5):e96013 [24828424.001]
  • [Cites] Iran J Basic Med Sci. 2015 Oct;18(10):967-73 [26730330.001]
  • [Cites] Int J Cancer. 2015 Oct 15;137(8):1979-89 [25885188.001]
  • [Cites] Biomed Res Int. 2013;2013:412379 [24102055.001]
  • [Cites] Crit Rev Food Sci Nutr. 2003;43(1):89-143 [12587987.001]
  • [Cites] Res Pharm Sci. 2016 Mar-Apr;11(2):145-51 [27168754.001]
  • [Cites] Acta Biomed. 2015 Sep 14;86(2):130-6 [26422426.001]
  • [Cites] Int J Antimicrob Agents. 2009 May;33(5):473-8 [19157800.001]
  • (PMID = 28465816.001).
  • [ISSN] 2008-5842
  • [Journal-full-title] Electronic physician
  • [ISO-abbreviation] Electron Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Iran
  • [Keywords] NOTNLM ; Camellia sinensis / Phytochemicals / catechins / chemopreventive / chemotherapeutic
  •  go-up   go-down


3. Park JH, Bae JH, Im SS, Song DK: Green tea and type 2 diabetes. Integr Med Res; 2014 Mar;3(1):4-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Green tea and type 2 diabetes.
  • Green tea and coffee consumption have been widely popular worldwide.
  • In addition to this caffeine effect, green tea and coffee consumption have always been at the center of discussions about human health, disease, and longevity.
  • In particular, green tea catechins are involved in many biological activities such as antioxidation and modulation of various cellular lipid and proteins.
  • Some reports also suggest that daily consumption of tea catechins may help in controlling type 2 diabetes.
  • However, other studies have reported that chronic consumption of green tea may result in hepatic failure, neuronal damage, and exacerbation of diabetes, suggesting that interindividual variations in the green tea effect are large.
  • This review will focus on the effect of green tea catechins extracted from the <i>Camellia sinensis</i> plant on type 2 diabetes and obesity, and the possible mechanistic explanation for the experimental results mainly from our laboratory.
  • It is hoped that green tea can be consumed in a suitable manner as a supplement to prevent the development of type 2 diabetes and obesity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Pharmacol. 2006 Jul 10;541(1-2):115-21 [16765345.001]
  • [Cites] Free Radic Biol Med. 2005 Sep 15;39(6):752-61 [16109305.001]
  • [Cites] FEBS Lett. 2005 Mar 14;579(7):1653-7 [15757656.001]
  • [Cites] Biochem Pharmacol. 2005 Nov 25;70(11):1560-7 [16216226.001]
  • [Cites] Biochem J. 2005 Mar 15;386(Pt 3):471-8 [15469417.001]
  • [Cites] J Antimicrob Chemother. 2004 Feb;53(2):225-9 [14688042.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83 [10092513.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jan;10(1):53-8 [11205489.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2010 Oct;382(4):303-10 [20711765.001]
  • [Cites] J Physiol Pharmacol. 2009 Dec;60(4):101-9 [20065503.001]
  • [Cites] Obesity (Silver Spring). 2009 Feb;17(2):310-7 [19008868.001]
  • [Cites] Arch Biochem Biophys. 1995 Oct 1;322(2):339-46 [7574706.001]
  • [Cites] Obes Res. 2003 Sep;11(9):1088-95 [12972679.001]
  • [Cites] Altern Med Rev. 2011 Jun;16(2):157-63 [21649457.001]
  • [Cites] Obes Res. 2005 Jun;13(6):982-90 [15976140.001]
  • [Cites] Pharmacol Res. 2007 Sep;56(3):237-47 [17656102.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1025-32 [12376503.001]
  • [Cites] Biol Pharm Bull. 2008 Jul;31(7):1403-9 [18591783.001]
  • [Cites] J Nutr. 2003 Oct;133(10):3262S-3267S [14519824.001]
  • [Cites] Biosci Biotechnol Biochem. 1997 Dec;61(12 ):1981-5 [9438978.001]
  • [Cites] Biochem Pharmacol. 2001 Sep 1;62(5):527-35 [11585049.001]
  • [Cites] Horm Metab Res. 2007 Oct;39(10):717-21 [17952832.001]
  • [Cites] Metabolism. 2007 Oct;56(10):1340-4 [17884442.001]
  • [Cites] J Agric Food Chem. 2009 Aug 12;57(15):6685-91 [19601628.001]
  • [Cites] Biosci Biotechnol Biochem. 2001 Dec;65(12):2638-43 [11826958.001]
  • [Cites] Br J Pharmacol. 2003 Oct;140(3):487-99 [12970085.001]
  • [Cites] Drug Metab Dispos. 1997 Sep;25(9):1045-50 [9311619.001]
  • [Cites] J Agric Food Chem. 2002 Nov 20;50(24):7182-6 [12428980.001]
  • [Cites] Ann Intern Med. 2006 Apr 18;144(8):554-62 [16618952.001]
  • [Cites] Mol Nutr Food Res. 2009 Mar;53(3):349-60 [19065584.001]
  • [Cites] Obesity (Silver Spring). 2007 Nov;15(11):2571-82 [18070748.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):29-33 [14551151.001]
  • [Cites] Cell Biol Int. 2007 Nov;31(11):1379-87 [17631393.001]
  • [Cites] J Nutr Biochem. 2003 Jun;14(6):326-32 [12873714.001]
  • [Cites] Mol Biochem Parasitol. 2009 Nov;168(1):113-6 [19577593.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 May;288(5):C1094-108 [15647388.001]
  • [Cites] Diabetes Res Clin Pract. 2006 Mar;71(3):356-8 [16169629.001]
  • [Cites] J Agric Food Chem. 2000 Nov;48(11):5618-23 [11087528.001]
  • [Cites] J Agric Food Chem. 2005 Jul 13;53(14):5695-701 [15998135.001]
  • [Cites] J Nutr Sci Vitaminol (Tokyo). 2005 Oct;51(5):335-42 [16392704.001]
  • [Cites] Nature. 2005 Jul 21;436(7049):356-62 [16034410.001]
  • [Cites] Free Radic Res. 2003 Aug;37(8):881-90 [14567448.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2013 Aug;386(8):733-45 [23620335.001]
  • [Cites] Diabetes Metab J. 2013 Jun;37(3):196-206 [23807923.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2009 Jun;379(6):551-64 [19221718.001]
  • [Cites] J Clin Invest. 2005 Aug;115(8):2047-58 [16075046.001]
  • [Cites] Nutrition. 2009 Oct;25(10):1047-56 [19535224.001]
  • [Cites] J Agric Food Chem. 2000 Oct;48(10):4576-80 [11052703.001]
  • (PMID = 28664072.001).
  • [ISSN] 2213-4220
  • [Journal-full-title] Integrative medicine research
  • [ISO-abbreviation] Integr Med Res
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; catechins / glucose uptake / green tea / obesity / type 2 diabetes
  •  go-up   go-down


Advertisement
4. Hong YH, Jung EY, Noh DO, Suh HJ: Physiological effects of formulation containing tannase-converted green tea extract on skin care: physical stability, collagenase, elastase, and tyrosinase activities. Integr Med Res; 2014 Mar;3(1):25-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physiological effects of formulation containing tannase-converted green tea extract on skin care: physical stability, collagenase, elastase, and tyrosinase activities.
  • BACKGROUND: Green tea contains numerous polyphenols, which have health-promoting effects.
  • The purpose of this study was to evaluate the effect of tannase-converted green tea extract (TGE) formulation on the physical stability and activities of skin-related enzymes.
  • RESULTS: The concentrations of epigallocatechin-3-gallate and epicatechin-3-gallate in green tea extract were greatly decreased to the extent of negligible level when treated with tannase.
  • The formulation containing 5% tannase-converted green tea extract showed relatively stable pH, precipitation, and color features for 16 weeks.
  • When TGE was added to the formulation, there was a significant increase in the inhibition of elastase and tyrosinase activities (<i>p</i> < 0.05) compared with the formulation containing 5% normal green tea extract.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Agric Food Chem. 2004 Aug 11;52(16):5183-6 [15291494.001]
  • [Cites] Biosci Biotechnol Biochem. 2008 Feb;72(2):303-11 [18256460.001]
  • [Cites] Clin Dermatol. 2008 Jul-Aug;26(4):367-74 [18691517.001]
  • [Cites] Anal Biochem. 1981 May 15;113(2):356-65 [6269461.001]
  • [Cites] Clin Dermatol. 2008 Jul-Aug;26(4):318-20 [18691509.001]
  • [Cites] Dermatol Surg. 2005 Jul;31(7 Pt 2):848-54; discussion 854 [16029677.001]
  • [Cites] Yao Xue Xue Bao. 2004 Jan;39(1):37-40 [15127579.001]
  • [Cites] J Am Acad Dermatol. 2005 Jun;52(6):1049-59 [15928624.001]
  • [Cites] Dermatol Surg. 2005 Jul;31(7 Pt 2):886-9; discussion 889 [16029683.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2007 Feb;23(1):48-56 [17254040.001]
  • [Cites] Biophys J. 2009 Feb;96(3):1026-35 [19186140.001]
  • [Cites] Biochim Biophys Acta. 1965 Nov 15;111(1):134-46 [5893781.001]
  • [Cites] Phytother Res. 2007 Sep;21(9):805-16 [17605157.001]
  • [Cites] Skin Pharmacol Physiol. 2010;23 (3):117-23 [20051712.001]
  • [Cites] Skin Pharmacol Physiol. 2009;22(6):299-304 [19786823.001]
  • [Cites] Doc Ophthalmol. 2003 Jan;106(1):13-6 [12675480.001]
  • [Cites] J Agric Food Chem. 2009 Sep 23;57(18):8496-503 [19711909.001]
  • [Cites] Biochem Soc Trans. 1996 Aug;24(3):790-5 [8878849.001]
  • [Cites] Am J Chin Med. 2005;33(4):535-46 [16173528.001]
  • [Cites] Life Sci. 1999;65(21):PL241-6 [10576599.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):14791-5 [2394696.001]
  • [Cites] Biochemistry. 1996 Jul 16;35(28):9090-6 [8703913.001]
  • [Cites] BMC Complement Altern Med. 2009 Aug 04;9:27 [19653897.001]
  • [Cites] J Agric Food Chem. 2000 Apr;48(4):1393-9 [10775403.001]
  • [Cites] Cell Mol Life Sci. 2004 Nov;61(22):2878-85 [15558216.001]
  • [Cites] J Nutr. 2001 Mar;131(3s):1010S-5S [11238807.001]
  • [Cites] J Nutr Biochem. 2007 May;18(5):287-96 [17049833.001]
  • [Cites] Mikrobiologiia. 1996 May-Jun;65(3):293-304 [8992239.001]
  • [Cites] J Agric Food Chem. 2003 May 7;51(10):2837-53 [12720364.001]
  • [Cites] Arch Dermatol Res. 1981;270(4):391-401 [7283467.001]
  • [Cites] Clin Exp Dermatol. 2001 Oct;26(7):592-9 [11696063.001]
  • [Cites] J Enzyme Inhib Med Chem. 2007 Feb;22(1):91-8 [17373553.001]
  • [Cites] Int J Biol Macromol. 2007 Jun 1;41(1):16-22 [17207851.001]
  • [Cites] Int J Cosmet Sci. 2002 Dec;24(6):357-66 [18494890.001]
  • [Cites] J Invest Dermatol. 1993 Feb;100(2 Suppl):209S-213S [8433009.001]
  • [Cites] FEBS Lett. 1974 Dec 15;49(2):156-8 [4216515.001]
  • (PMID = 28664075.001).
  • [ISSN] 2213-4220
  • [Journal-full-title] Integrative medicine research
  • [ISO-abbreviation] Integr Med Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; elastase / green tea / stability / tannase / tyrosinase
  •  go-up   go-down


5. Roomi MW, Kalinovsky T, Niedzwiecki A, Rath M: Modulation of MMP-2 and -9 secretion by cytokines, inducers and inhibitors in human melanoma A-2058 cells. Oncol Rep; 2017 Jun;37(6):3681-3687

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At near confluence, the cells were washed with PBS and incubated in serum-free media with phorbol 12-myristate 13-acetate (PMA) at 10, 25, 50 and 100 ng/ml; TNF-α and IL-1β at 0.1, 1, 10 and 25 ng/ml; LPS at 10, 25, 50 and 100 µg/ml; epigallocatechin gallate (EGCG) and doxycycline (Dox) at 10, 25, 50 and 100 µM without and with PMA; a nutrient mixture (NM) containing lysine, proline, ascorbic acid and green tea extract without and with PMA at 10, 50, 100, 500 and 1,000 µg/ml; actinomycin D and cyclohexamide at 2 and 4 µM; retinoic acid and dexamethasone at 50 µM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28440509.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


6. Seo EJ, Wu CF, Ali Z, Wang YH, Khan SI, Walker LA, Khan IA, Efferth T: Both Phenolic and Non-phenolic Green Tea Fractions Inhibit Migration of Cancer Cells. Front Pharmacol; 2016;7:398

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Both Phenolic and Non-phenolic Green Tea Fractions Inhibit Migration of Cancer Cells.
  • Green tea consumption is associated with chemoprevention of many cancer types.
  • Fresh tea leaves are rich in polyphenolic catechins, which can constitute up to 30% of the dry leaf weight.
  • While the polyphenols of green tea have been well investigated, it is still largely unknown, whether or not non-phenolic constituents also reveal chemopreventive and anti-metastatic effects.
  • In this study, we investigated the effects of a fraction of green tea rich in phenolic compounds (PF), a non-phenolic fraction (NPF), which contains glyceroglycolipids (GGL), and a pure glyceroglycolipid compound isolated from the non-phenolic fraction in human cancer.
  • Dried green tea leaves were extracted and applied to a Sephadex LH-20 column.
  • The resazurin reduction assay was used to investigate the cytotoxicity of green tea samples toward human HepG2 hepatocellular carcinoma and normal AML12 hepatocytes cells.
  • The scratch migration assay was used to investigate the effects of green tea samples on cell migration <i>in vitro</i>.
  • PF and NPF were prepared from methanol extract of green tea.
  • All three green tea samples did not show significant cytotoxic activity up to 10 μg/mL in both HepG2 and AML12 cells, whereas cytotoxicity of the control drug doxorubicin was observed with both cell lines (IC<sub>50</sub> on AML12: 0.024 μg/mL, IC<sub>50</sub> on HepG2: 2.103 μg/mL).
  • We identified three sets of genes differentially expressed upon treatment with the green tea samples.
  • HepG2 and U2OS cells treated with green tea extracts showed the delayed closures.
  • Besides, the number of distinct tubulin filaments decreased upon treatment with green tea samples.
  • We identified not only PF, but also glyceroglycolipids in NPF as contributing factors to the chemopreventive effects of green tea.
  • Both PF and NPF of green tea inhibited cancer cell migration by the disassembly of microtubules, even though they were not cytotoxic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Nutr. 2006 Apr;25(2):79-99 [16582024.001]
  • [Cites] Urol Oncol. 2005 Mar-Apr;23(2):108-13 [15869995.001]
  • [Cites] Adv Cancer Res. 1993;62:19-64 [8109319.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1234-40 [16424063.001]
  • [Cites] J Nutr. 2002 Aug;132(8):2307-11 [12163680.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1442-6 [12627508.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6493-501 [17616711.001]
  • [Cites] Biotechniques. 2009 Apr;46(4):265-74 [19450233.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6907-15 [17638902.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4524-9 [10200295.001]
  • [Cites] Nature. 1997 Jun 5;387(6633):561 [9177339.001]
  • [Cites] Chin Med. 2010 Apr 06;5:13 [20370896.001]
  • [Cites] Antiviral Res. 2003 Apr;58(2):167-73 [12742577.001]
  • [Cites] J Cell Biochem. 2001;82(3):387-98 [11500915.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4610-7 [10493515.001]
  • [Cites] J Cell Biochem. 1997 Oct 1;67(1):55-65 [9328839.001]
  • [Cites] Phytomedicine. 2015 Apr 15;22(4):438-43 [25925965.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1675-83 [15746073.001]
  • [Cites] Carcinogenesis. 2008 Oct;29(10):1986-93 [18586691.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3010-4 [1557406.001]
  • [Cites] Fitoterapia. 2013 Oct;90:151-9 [23892001.001]
  • [Cites] J Biol Chem. 2008 Feb 8;283(6):3050-8 [18079119.001]
  • [Cites] Crit Rev Food Sci Nutr. 1997 Dec;37(8):693-704 [9447270.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Jun;4(4):345-54 [15180500.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jun;48(6):1968-73 [15155186.001]
  • [Cites] Biomed Res. 2005 Oct;26(5):187-92 [16295694.001]
  • [Cites] Cancer Metastasis Rev. 2010 Sep;29(3):435-45 [20714789.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8118-21 [14678963.001]
  • [Cites] Nat Protoc. 2007;2(2):329-33 [17406593.001]
  • [Cites] Toxicol Lett. 2004 Apr 15;150(1):43-56 [15068824.001]
  • [Cites] Ann N Y Acad Sci. 2001 Apr;928:274-80 [11795518.001]
  • [Cites] Prev Med. 1992 May;21(3):334-50 [1614995.001]
  • [Cites] Cancer Lett. 2009 Nov 1;284(2):122-30 [19303207.001]
  • [Cites] Biomed Res. 2007 Feb;28(1):43-8 [17379956.001]
  • [Cites] FASEB J. 2001 Sep;15(11):2022-4 [11511526.001]
  • [Cites] Mol Nutr Food Res. 2005 Jan;49(1):43-51 [15538715.001]
  • [Cites] Mol Carcinog. 2012 Mar;51(3):280-9 [21882252.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2001 Feb;128(2):153-64 [11239828.001]
  • [Cites] Analyst. 2001 Jun;126(6):816-20 [11445943.001]
  • [Cites] J Nutr Biochem. 2003 Jun;14(6):326-32 [12873714.001]
  • [Cites] Avicenna J Phytomed. 2015 Mar-Apr;5(2):84-97 [25949949.001]
  • [Cites] Eur J Biochem. 2000 Sep;267(17):5421-6 [10951200.001]
  • [Cites] J Nutr. 2003 Oct;133(10):3303S-3309S [14519830.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2015 Dec;29(6):919-28 [26651253.001]
  • [Cites] Biol Chem. 2002 Mar-Apr;383(3-4):663-70 [12033455.001]
  • [Cites] Nat Struct Mol Biol. 2004 Apr;11(4):380-1 [15024383.001]
  • [Cites] Trends Cell Biol. 2005 Feb;15(2):76-83 [15695094.001]
  • [Cites] J Exp Ther Oncol. 2002 Nov-Dec;2(6):350-9 [12440226.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):130-5 [14618627.001]
  • [Cites] Evid Based Complement Alternat Med. 2012;2012:726025 [23118796.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4414-9 [9331105.001]
  • [Cites] J Biol Chem. 2015 Jul 10;290(28):17145-53 [25957409.001]
  • [Cites] J Nutr Biochem. 2004 Sep;15(9):506-16 [15350981.001]
  • [Cites] J Immunol. 2003 Apr 15;170(8):4335-41 [12682270.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2735-46 [15814656.001]
  • [Cites] Int J Cancer. 1997 Jan 27;70(3):255-8 [9033623.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):8049-56 [16140980.001]
  • (PMID = 28194107.001).
  • [ISSN] 1663-9812
  • [Journal-full-title] Frontiers in pharmacology
  • [ISO-abbreviation] Front Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; chemoprevention / green tea / microarray / nutrigenomics / theaceae
  •  go-up   go-down


7. Dekant W, Fujii K, Shibata E, Morita O, Shimotoyodome A: Safety assessment of green tea based beverages and dried green tea extracts as nutritional supplements. Toxicol Lett; 2017 Aug 05;277:104-108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety assessment of green tea based beverages and dried green tea extracts as nutritional supplements.
  • The safety of green tea infusions and green tea extract (GTE)-based products is reviewed regarding catechins.
  • Epigallocatechin 3-gallate (EGCG), the major catechin present in green tea, is suspected of being responsible for liver toxicity reported in humans consuming food supplements.
  • Intake of EGCG with green tea infusions and GTE-based beverages is up to about 450mg EGCG/person/day in Europe and higher in Asia.
  • Consumption of green tea is not associated with liver damage in humans, and green tea infusion and GTE-based beverages are considered safe in the range of historical uses.
  • Use of NOAELs from bolus administration to derive a tolerable upper intake level applying the margin of safety concept results in acceptable EGCG-doses lower than those from one cup of green tea.
  • Thus, a tolerable upper intake level of 300mg EGCG/person/day is proposed for food supplements; this gives a twofold safety margin to clinical studies that did not report liver effects and a margin of safety of 100 to the NOAELs in animal studies with dietary administration of green tea catechins.
  • [MeSH-major] Camellia sinensis / chemistry. Catechin / analogs & derivatives. Dietary Supplements. Food Safety. Plant Extracts / analysis. Tea / chemistry. Teas, Herbal / analysis
  • [MeSH-minor] Animals. Consumer Product Safety. Hazard Analysis and Critical Control Points. Humans. No-Observed-Adverse-Effect Level. Recommended Dietary Allowances. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28655517.001).
  • [ISSN] 1879-3169
  • [Journal-full-title] Toxicology letters
  • [ISO-abbreviation] Toxicol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Tea; 0 / Teas, Herbal; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate
  • [Keywords] NOTNLM ; Catechins / Food supplements / Green tea / Safety assessment
  •  go-up   go-down


8. Singhal K, Raj N, Gupta K, Singh S: Probable benefits of green tea with genetic implications. J Oral Maxillofac Pathol; 2017 Jan-Apr;21(1):107-114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probable benefits of green tea with genetic implications.
  • Tea is produced from the <i>Camellia sinensis</i> plant and can generally be divided into categories based on how they are processed.
  • In general, green tea that is unfermented <i>C. sinensis</i> has been considered superior to black tea in health benefits.
  • Oral cavity oxidative stress and inflammation, consequent cigarettes due to nicotine and acrolein, may be reduced in the presence of green tea polyphenols.
  • In addition, green tea polyphenols can close down halitosis through modification of odorant sulfur components.
  • Usually, green tea defends healthy cells from malignant transformation and locally has the ability to induce apoptosis in oral cancer cells.
  • In unison, there is an increasing implication in the health benefits of green tea in the field of oral health.
  • This review will cover recent findings on the therapeutic properties and anticancer health benefits of green tea.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Nutr. 2006 Apr;25(2):79-99 [16582024.001]
  • [Cites] Eur J Oral Sci. 2010 Apr;118(2):145-50 [20487003.001]
  • [Cites] Food Chem Toxicol. 1997 Aug;35(8):827-33 [9350228.001]
  • [Cites] J Periodontol. 2009 Mar;80(3):372-7 [19254120.001]
  • [Cites] Br J Nutr. 2009 Dec;102(12):1790-802 [19751534.001]
  • [Cites] Molecules. 2007 May 03;12(5):946-57 [17873830.001]
  • [Cites] J Altern Complement Med. 2005 Jun;11(3):521-8 [15992239.001]
  • [Cites] Eur J Clin Nutr. 1996 Jan;50(1):28-32 [8617188.001]
  • [Cites] Nutrition. 2002 May;18(5):443-4 [11985958.001]
  • [Cites] Caries Res. 1999 Nov-Dec;33(6):441-5 [10529529.001]
  • [Cites] Arch Oral Biol. 2012 May;57(5):429-35 [22226360.001]
  • [Cites] J Periodontal Res. 2002 Dec;37(6):433-8 [12472837.001]
  • [Cites] Anticancer Agents Med Chem. 2006 Sep;6(5):389-406 [17017850.001]
  • [Cites] J Periodontal Res. 2004 Oct;39(5):300-7 [15324350.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4524-9 [10200295.001]
  • [Cites] Biol Psychiatry. 2007 Dec 15;62(12):1353-62 [17624318.001]
  • [Cites] J Periodontol. 1993 Jul;64(7):630-6 [8396176.001]
  • [Cites] Am J Clin Nutr. 2007 Oct;86(4):1243-7 [17921409.001]
  • [Cites] BMC Complement Altern Med. 2014 Aug 30;14:322 [25175005.001]
  • [Cites] Arch Intern Med. 2003 Jun 23;163(12):1448-53 [12824094.001]
  • [Cites] Antiviral Res. 2003 Apr;58(2):167-73 [12742577.001]
  • [Cites] J Indian Soc Periodontol. 2012 Apr;16(2):161-7 [23055579.001]
  • [Cites] J Cell Biochem. 2001;82(3):387-98 [11500915.001]
  • [Cites] Cancer Lett. 1998 Jul 17;129(2):173-9 [9719459.001]
  • [Cites] Arch Biochem Biophys. 2000 Apr 15;376(2):338-46 [10775421.001]
  • [Cites] Int J Cardiol. 2006 Apr 14;108(3):301-8 [15978686.001]
  • [Cites] J Periodontal Res. 2010 Feb;45(1):23-30 [19602116.001]
  • [Cites] Explore (NY). 2006 Nov-Dec;2(6):531-9 [17113495.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):6009-14 [12719524.001]
  • [Cites] J Expo Sci Environ Epidemiol. 2008 Mar;18(2):158-66 [17410113.001]
  • [Cites] Oral Microbiol Immunol. 2004 Apr;19(2):118-20 [14871352.001]
  • [Cites] Biochem Pharmacol. 1999 Sep 15;58(6):911-5 [10509743.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Mar 22;292(1):94-101 [11890677.001]
  • [Cites] Biosci Biotechnol Biochem. 1996 May;60(5):745-9 [8704303.001]
  • [Cites] J Med Chem. 2007 Jan 25;50(2):264-71 [17228868.001]
  • [Cites] Rev Saude Publica. 2004 Feb;38(1):100-5 [14963548.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jun;48(6):1968-73 [15155186.001]
  • [Cites] Antiviral Res. 1993 Aug;21(4):289-99 [8215301.001]
  • [Cites] Ann N Y Acad Sci. 2001 Apr;928:274-80 [11795518.001]
  • [Cites] J Oral Pathol Med. 2007 Nov;36(10):588-93 [17944751.001]
  • [Cites] Ann Nutr Metab. 2004;48(2):95-102 [14988639.001]
  • [Cites] Clin Nutr. 2006 Oct;25(5):790-6 [16698148.001]
  • [Cites] Proc Soc Exp Biol Med. 1999 Apr;220(4):218-24 [10202392.001]
  • [Cites] J Clin Aesthet Dermatol. 2012 Feb;5(2):34-41 [22468171.001]
  • [Cites] Arch Pharm Res. 1998 Jun;21(3):348-52 [9875456.001]
  • [Cites] Eur J Pharmacol. 2004 Oct 1;500(1-3):177-85 [15464031.001]
  • [Cites] Tob Induc Dis. 2003 Sep 15;1(3):219-26 [19570263.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2001 Feb;128(2):153-64 [11239828.001]
  • [Cites] Heart. 2004 Dec;90(12):1485-6 [15547040.001]
  • [Cites] J Endod. 2010 Jan;36(1):83-6 [20003940.001]
  • [Cites] Drug Metabol Drug Interact. 2004;20(1-2):43-56 [15283302.001]
  • [Cites] J Am Coll Nutr. 2002 Feb;21(1):1-13 [11838881.001]
  • [Cites] Pharmacol Res. 2011 Aug;64(2):105-12 [21624470.001]
  • [Cites] Exp Toxicol Pathol. 2005 Jul;57 Suppl 1:43-73 [16092717.001]
  • [Cites] Iran J Basic Med Sci. 2012 May;15(3):880-4 [23493325.001]
  • [Cites] J Indian Soc Periodontol. 2011 Jan;15(1):18-22 [21772716.001]
  • [Cites] J Nutr Biochem. 2004 Sep;15(9):506-16 [15350981.001]
  • [Cites] J Immunol. 2003 Apr 15;170(8):4335-41 [12682270.001]
  • [Cites] Phytother Res. 2004 Aug;18(8):624-7 [15476306.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):132-7 [14744744.001]
  • [Cites] J Agric Food Chem. 2004 Mar 24;52(6):1688-92 [15030231.001]
  • [Cites] Toxicol Sci. 2006 Feb;89(2):547-53 [16280382.001]
  • (PMID = 28479696.001).
  • [ISSN] 0973-029X
  • [Journal-full-title] Journal of oral and maxillofacial pathology : JOMFP
  • [ISO-abbreviation] J Oral Maxillofac Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Keywords] NOTNLM ; Antioxidants / Camellia sinensis / cancer / tea
  •  go-up   go-down


9. He Y, Tan D, Mi Y, Zhou Q, Ji S: Epigallocatechin-3-gallate attenuates cerebral cortex damage and promotes brain regeneration in acrylamide-treated rats. Food Funct; 2017 Jun 21;8(6):2275-2282

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the neuroprotective effects of epigallocatechin-3-gallate (EGCG), the most abundant polyphenol in green tea, on ACR-treated rat brain.
  • [MeSH-major] Acrylamide / toxicity. Brain Diseases / drug therapy. Camellia sinensis / chemistry. Catechin / analogs & derivatives. Cerebral Cortex / drug effects. Neuroprotective Agents / administration & dosage. Plant Extracts / administration & dosage
  • [MeSH-minor] Animals. Brain-Derived Neurotrophic Factor / metabolism. Cyclooxygenase 2 / metabolism. Humans. Male. Nitric Oxide Synthase Type II / metabolism. Rats. Rats, Sprague-Dawley. Regeneration / drug effects. Tea / chemistry. beta-Galactosidase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28561817.001).
  • [ISSN] 2042-650X
  • [Journal-full-title] Food & function
  • [ISO-abbreviation] Food Funct
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Brain-Derived Neurotrophic Factor; 0 / Neuroprotective Agents; 0 / Plant Extracts; 0 / Tea; 20R035KLCI / Acrylamide; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.2.1.23 / beta-Galactosidase
  •  go-up   go-down


10. Shin CM, Lee DH, Seo AY, Lee HJ, Kim SB, Son WC, Kim YK, Lee SJ, Park SH, Kim N, Park YS, Yoon H: Green tea extracts for the prevention of metachronous colorectal polyps among patients who underwent endoscopic removal of colorectal adenomas: A randomized clinical trial. Clin Nutr; 2017 Jan 29;
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Green tea extracts for the prevention of metachronous colorectal polyps among patients who underwent endoscopic removal of colorectal adenomas: A randomized clinical trial.
  • OBJECTIVES: To determine the preventive effect of green tea extract (GTE) supplements on metachronous colorectal adenoma and cancer in the Korean population.
  • However, there were no significant differences between the 2 groups in terms of body mass index, dietary intakes, serum lipid profiles, fasting serum glucose, and serum C-reactive protein levels (all p > 0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
  • (PMID = 28209333.001).
  • [ISSN] 1532-1983
  • [Journal-full-title] Clinical nutrition (Edinburgh, Scotland)
  • [ISO-abbreviation] Clin Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Colon polyps / Epigallocatechin gallate / Green tea / Recurrence risk
  •  go-up   go-down






Advertisement